Breakthrough Therapy Designation
What a definition is not
A definition is SPEQ’s plain-language decode of how a term is used in practice, cited to the documents that define it. It is a practitioner reference, not legal or regulatory advice, it does not replace the definition in the source, and where a regulator’s wording differs the regulator’s wording governs.
Breakthrough Therapy is an FDA expedited-program designation for a drug intended to treat a serious condition where preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available therapies on a clinically significant endpoint. It brings intensive FDA guidance starting early in development, including organizational commitment and cross-disciplinary review team involvement.
The “substantial improvement” bar is what distinguishes Breakthrough Therapy from Fast Track designation, which requires only that the drug address an unmet medical need — Breakthrough requires actual preliminary clinical evidence of a meaningfully better effect, not just promise or mechanism-based rationale.
A drug with Breakthrough Therapy designation is eligible for all Fast Track features plus more frequent formal meetings with FDA to discuss an efficient development plan, and organizational commitment involving senior FDA managers — it does not lower the evidentiary bar for approval, but it changes how much interactive guidance FDA provides while that evidence is generated.
- —Requires preliminary clinical evidence of substantial improvement over available therapy
- —Distinguished from Fast Track, which needs only an unmet-need showing, not comparative evidence
- —Brings intensive, early, cross-disciplinary FDA engagement and more frequent meetings
- —Does not lower the evidentiary standard required for eventual approval
FD&C Act §506(a) (as amended by FDASIA, 2012); FDA guidance “Expedited Programs for Serious Conditions — Drugs and Biologics” (2014)
Frequently asked questions
What is Breakthrough Therapy Designation?
Breakthrough Therapy is an FDA expedited-program designation for a drug intended to treat a serious condition where preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available therapies on a clinically significant endpoint. It brings intensive FDA guidance starting early in development, including organizational commitment and cross-disciplinary review team involvement.
Which regulations cover Breakthrough Therapy Designation?
FD&C Act §506(a) (as amended by FDASIA, 2012); FDA guidance “Expedited Programs for Serious Conditions — Drugs and Biologics” (2014)